[No-reflow: update on diagnosis, pathophysiology and therapeutic strategies]

Area of Science:

• Cardiology
• Interventional Cardiology
• Vascular Biology

Background:

• Primary percutaneous coronary intervention (PCI) is the standard reperfusion therapy for ST-segment elevation myocardial infarction.
• Epicardial flow restoration via PCI does not always translate to effective myocardial tissue reperfusion.
• Microvascular obstruction, termed 'no-reflow', complicates primary PCI in 30-60% of patients.

Purpose of the Study:

• To review the complex pathophysiology of no-reflow.
• To discuss diagnostic tools for identifying no-reflow.
• To highlight therapeutic targets for managing no-reflow.

Main Methods:

• Review of current literature on no-reflow pathophysiology.
• Analysis of diagnostic imaging and functional assessment techniques.
• Evaluation of pharmacological and interventional treatment strategies.

Main Results:

• No-reflow results from a combination of distal embolization, ischemia-reperfusion injury, and intrinsic microvascular dysfunction.
• Effective diagnosis relies on a combination of angiographic findings and myocardial contrast echocardiography or MRI.
• Therapeutic strategies aim to prevent microvascular damage and improve microcirculatory function.

Conclusions:

• No-reflow is a significant complication of primary PCI, negatively impacting clinical outcomes.
• Understanding the multifaceted pathophysiology is crucial for developing effective treatments.
• Further research into novel therapeutic targets is warranted to improve patient prognosis.